Feedback from Endocrinologists on ADA 2023 Presentations

This document is a report detailing feedback gathered from 12 practicing endocrinologists regarding key presentations from the American Diabetes Association (ADA) 2023 Scientific Sessions held in San Diego. The report outlines the physicians' opinions on various diabetes treatments discussed at the conference, including Eli Lilly's tirzepatide and retatrutide, Biomea Fusion's BMF-219, and Vertex's VX-880. The endocrinologists expressed enthusiasm for tirzepatide's weight loss benefits compared to Novo Nordisk's Ozempic, while also highlighting retatrutide's potential to capture market share due to its favorable weight loss data. Additionally, the report includes insights on BMF-219's innovative approach to treating type 2 diabetes and VX-880's promise for type 1 diabetes patients. The document captures a range of perspectives, reflecting both excitement and skepticism regarding the new treatments presented at the ADA conference.